AVEO Pharmaceuticals announced that it has initiated patient enrollment in a multi-center Phase 2 exploratory biomarker study of tivozanib for the treatment of renal cell carcinoma (RCC). This multi-center, single-arm study is designed to evaluate biomarkers of tivozanib in approximately 100 patients with RCC who had a prior nephrectomy at 25 sites in the U.S. and Canada. A key primary objective of the study is to evaluate biomarkers in blood and archived tissue samples and their correlation with tivozanib clinical activity and/or drug-related toxicity.
Tivozanib is designed to optimally block the VEGF pathway by inhibiting all three VEGF receptors. Each of the three receptors of the VEGF pathway play an important role in angiogenesis (the formation of new blood vessels), which is critical in cancer cell growth.
For more information call (617) 299-5000 or visit www.aveopharma.com.